N-(3-(4-(3-(4-Amino-5-chloro-2-methoxyphenyl)-3-oxopropyl)piperidin-1-yl)propyl)-4-methoxybenzenesulfonamide

ID: ALA4748287

Chembl Id: CHEMBL4748287

PubChem CID: 162649188

Max Phase: Preclinical

Molecular Formula: C25H34ClN3O5S

Molecular Weight: 524.08

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(S(=O)(=O)NCCCN2CCC(CCC(=O)c3cc(Cl)c(N)cc3OC)CC2)cc1

Standard InChI:  InChI=1S/C25H34ClN3O5S/c1-33-19-5-7-20(8-6-19)35(31,32)28-12-3-13-29-14-10-18(11-15-29)4-9-24(30)21-16-22(26)23(27)17-25(21)34-2/h5-8,16-18,28H,3-4,9-15,27H2,1-2H3

Standard InChI Key:  XYUNOSQVXMZGGS-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4748287

    ---

Associated Targets(Human)

HTR6 Tchem Serotonin 6 (5-HT6) receptor (9749 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

HTR4 Serotonin 4 (5-HT4) receptor (2870 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 524.08Molecular Weight (Monoisotopic): 523.1908AlogP: 3.98#Rotatable Bonds: 12
Polar Surface Area: 110.96Molecular Species: NEUTRALHBA: 7HBD: 2
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 3#RO5 Violations (Lipinski): 1
CX Acidic pKa: 10.45CX Basic pKa: 7.85CX LogP: 2.80CX LogD: 2.22
Aromatic Rings: 2Heavy Atoms: 35QED Weighted: 0.25Np Likeness Score: -1.15

References

1. Yahiaoui S,Hamidouche K,Ballandonne C,Davis A,de Oliveira Santos JS,Freret T,Boulouard M,Rochais C,Dallemagne P.  (2016)  Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease.,  121  [PMID:27266998] [10.1016/j.ejmech.2016.05.048]

Source